Mikhail Blagosklonny Uses TOR Signaling to Find Cancer Treatment

Cancer is a leading cause of death in the health care sector. Consequently, physicians, researchers, scientists as well as donors have channeled their attention and contribution towards the life-threatening disease. The aim of this concentration and contribution is developing modern treatments for cancer. One such individual who has massively contributed to the first against cancer is Mikhail Blagosklonny. As a dedicated scientist, Mikhail has made numerous contributions towards the battle against cancer. He is a specialist in oncology with strong academic credentials that better place him at the center of research institutions for cancer. Some of his theories in cancer as well as age-related life threatening diseases have brought forth a new era in cancer treatment.

Research

Mikhail Blagosklonny is a prominent research scientist who specializes in oncology. He has authored several books in regards to the battle against cancer. He has also co-authored many chapters as well as research reviews on molecular as well as cellular biology. His interests lie on cell cycle, autophagy as well as apoptosis. His works on the molecular hypothesis of aging have vastly been cited in several books. Towards this end, Blagosklonny suggested that the target of rapamycin plays a pivotal role in the battle against cancer and age-related disease.

Learn more: https://www.ncbi.nlm.nih.gov/pubmed/?term=blagosklonny

TOR

Mikhail Blagosklonny states that TOR signaling is responsible for prolonging cell life. This occurs when there is an inhibition of apoptosis. This in return delays autophagy by promoting the synthesis of proteins. Mikhail Blagosklonny states that it is vital to understand these processes as the sequences play a significant role in reaching advanced treatments. He also proposed that the overexpression of TOR Signaling leads to the growth of cancer cells. He, therefore, suggested that the reduction would regulate the growth of cancer cells by providing treatment.

Work and Education

Mikhail Blagosklonny is not only a research scientist but also a scholar. Currently, he serves at the Cancer Institute Research of Roswell Park. He was appointed to the position in 2009 and has been committed to developing treatment therapies. His extensive experience played a pivotal role in his appointment to this post. Through the same vast experience was Mikhail Blagosklonny trusted with Ordway Research Institute. He served as a research scientist in the organization. Mikhail Blagosklonny has strong academic credentials that have supported his participation in the medical field. He is a specialist majoring in internal medicine as well as experimental medicine. View Mikhail’s profile on Google Scholar

Conclusion

The alumnus of the glitzy First Pavlov Medical University is the serving editorial leader for Oncotarget. This is a peer-reviewed journal that seeks to disseminate scientific and medical information regarding various diseases and their treatments. The journal is published weekly or biweekly depending on the demand. It can also be printed upon request. Mikhail Blagosklonny commits to using his talent and academic credentials to find treatment fe’or cancer as well as age-related diseases.

Advances in Stem Cell Research Improves Quality of Life For People With Pulmonary Disease

The Third International Congress on Responsible Stem Cell Research met in Padua, Italy in November 2016. The purpose of this event was to review and discuss the application and progress of stem cell therapy and look into the future of where technology is moving on lung disease.

Dr. Jack Coleman, Jr. of the Baylor College of Medicine, attended this conference and spoke to the audience stating that “Our responsibility is to give the best, safest treatment to patients to relieve pain and suffering and prolong quality of life.” The quality of life is the goal the Lung Institute strives to achieve in administering the new technology of stem cell therapy. Replacing previous procedures with the latest IV process has not merely bettered the quality of life for people suffering from lung disease, but trimmed the cost of treatments of lung disease and in hospital visits and expenses.

The minimally invasive stem cell treatment is proving to be a huge breakthrough in the quality of life for people suffering from pulmonary disease. Dr. Coleman discussed how the new processes are regulated, reducing time and costs while increasing the availability of treatments to more patients. It is no enigma that this new stem cell technology is improving the quality of life for many people suffering from lung diseases like COPD, Chronic Bronchitis, Emphysema, Pulmonary Fibrosis, Bronchiectasis, Interstitial Lung Disease and Pneumoconiosis.

For more info regarding the Third International Congress, please see http://www.prweb.com/releases/2016/11/prweb13867190.htm for the complete event recap. Also check out this article: http://lifestylesafter50.com/adult-stem-cell-therapy-at-the-lung-institute-helps-pulmonary-fibrosis-patient/.

The facilities also offer Bone Marrow option for stem cell treatments in addition to the Venous stem cell therapy. The venous stem cell treatment is the latest and least invasive blood-derived treatment option, simply depending on the patient’s health and any heart condition, the venous therapy method is the least traumatic for the patient. The patient’s doctor will decide which method is the best treatment for the well-being of the soul.

The Lung Institute has clinics located in Tampa, FL – 813-642-6417, Nashville, TN – 615-988-1051, Scottsdale, AZ – 480-378-6658, Pittsburgh, PA – 724-635-4302, and Dallas, TX – 214-935-1699. Contact the Lung Institute at (800) 729-3065 to speak to a patient coordinator, or visit their website at  https://lunginstitute.com/treatment/venous/ for more info. Read the patirnts testimonials on lunginstitute.com.